Tukysa (Tucatinib Tablets) is a kinase inhibitor used in combination with trastuzumab and capecitabine to treat adult patients with advanced unresectable or metastatic HER2-Positive Breast Cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Dosage: The recommended dosage of Tukysa is 300 mg, which should be taken orally twice daily along with trastuzumab and capecitabine until the disease is progressive or unacceptable toxicity occurs. Swallow the tablets of Tukysa whole and not to chew, crush, or split prior to swallowing. Do not ingest tablets if it is broken, cracked, or not otherwise intact. Administer the tukysa dosage around 12 hours apart and at the persistent time each day with or without a meal. In case the patient vomits or misses a dose of Tukysa, the patient should take the next dose at its usual scheduled time. When given along with Tukysa, the recommended dosage of capecitabine is 1000 mg/m2 orally twice daily taken within 30 minutes after a meal. Tukysa and capecitabine can be taken at the same time.
Side Effects: The most commonly reported tukysa side effects (incidence ≥20%) include:
- decreased appetite
- abdominal pain
- palmar-plantar erythrodysesthesia
Warnings and Precautions:
- Tucatinib 150 Mg Tablet has been associated with severe diarrhea. Instruct patients on how to manage diarrhea and to inform their health specialist immediately if there is any change in bowel.
- Monitor ALT, AST, and bilirubin prior to starting tucatinib 50 mg / 150 mg, every 3 weeks during treatment, and as clinically indicated.
- Tucatinib has been associated with severe hepatotoxicity. Patients should report signs and symptoms of liver dysfunction to their health specialist immediately.
- The tukysa fda label drug can cause fetal harm if administered to a pregnant woman. Females of reproductive age should use apt contraception during treatment and for at least 7 days following the last dose.
- Women should not breastfeed during treatment with Tucatinib and for at least 7 days following the last dose.